User contributions
Jump to navigation
Jump to search
- 16:37, 19 April 2024 diff hist +230 m Opioid Conversion Table current
- 16:22, 19 April 2024 diff hist +745 m B-cell acute lymphoblastic leukemia, pediatric →References
- 12:34, 19 April 2024 diff hist 0 m Mantle cell lymphoma →Lenalidomide monotherapy {{#subobject:b5de78|Regimen=1}}
- 12:32, 19 April 2024 diff hist +594 m Head and neck cancer →Methotrexate monotherapy {{#subobject:0e90b2|Regimen=1}}
- 12:30, 19 April 2024 diff hist +280 m Glioblastoma →Carmustine & RT {{#subobject:ee9fbd|Regimen=1}}
- 12:25, 19 April 2024 diff hist +293 m Head and neck cancer →Cetuximab monotherapy {{#subobject:4b973b|Regimen=1}}
- 12:24, 19 April 2024 diff hist +933 m Head and neck cancer →Docetaxel monotherapy {{#subobject:623c3f|Regimen=1}}
- 12:15, 19 April 2024 diff hist -36 m B-cell acute lymphoblastic leukemia, Ph-positive →Dasatinib, Vincristine, Prednisone {{#subobject:71a41c|Regimen=1}}
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:bd7f87|Variant=1}}
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →FLAG-Ida {{#subobject:d8c75b|Regimen=1}}
- 12:10, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:c9nqa0|Variant=1}}
- 11:17, 19 April 2024 diff hist +337 m Chronic lymphocytic leukemia →Ofatumumab monotherapy {{#subobject:75bd7e|Regimen=1}}
- 11:12, 19 April 2024 diff hist -4 m Breast cancer, triple negative
- 11:11, 19 April 2024 diff hist -1 m Breast cancer, triple negative →Paclitaxel & Pembrolizumab {{#subobject:2g8gua|Regimen=1}}
- 11:07, 19 April 2024 diff hist +29 m Breast cancer, BRCA-mutated →Regimen variant #2, 300 mg twice per day {{#subobject:3b0774|Variant=1}}
- 11:00, 19 April 2024 diff hist +8 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 11:00, 19 April 2024 diff hist +2 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 10:59, 19 April 2024 diff hist -65 m Colorectal cancer, MSI-H or dMMR →Pembrolizumab monotherapy {{#subobject:5aa59d|Regimen=1}}
- 00:36, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}}
- 00:35, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Regimen {{#subobject:d1dde0|Variant=1}}
- 00:35, 19 April 2024 diff hist +29 m Esophageal squamous cell carcinoma →Camrelizumab monotherapy {{#subobject:c701c3|Regimen=1}}
- 00:29, 19 April 2024 diff hist -39 m Non-small cell lung cancer, nonsquamous →Regimen variant #2, 5/500 x 4, then maintenance pem x 2y {{#subobject:1mwjm3|Variant=1}}
- 00:19, 19 April 2024 diff hist +1,816 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:17, 19 April 2024 diff hist +1,791 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:16, 19 April 2024 diff hist +1,794 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 00:14, 19 April 2024 diff hist +686 m Ovarian cancer, HRD-positive
- 00:14, 19 April 2024 diff hist -686 m Ovarian cancer, HRD-positive
- 00:13, 19 April 2024 diff hist +1,813 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 23:47, 18 April 2024 diff hist -2 m Gastric cancer, HER2-positive →Regimen {{#subobject:577cd6|Variant=1}}
- 23:44, 18 April 2024 diff hist +3 m Peripheral T-cell lymphoma →References
- 23:44, 18 April 2024 diff hist +19 m Peripheral T-cell lymphoma →Gemcitabine monotherapy {{#subobject:7dbc1c|Regimen=1}}
- 23:43, 18 April 2024 diff hist +2 m Peripheral T-cell lymphoma - historical →References
- 23:39, 18 April 2024 diff hist +807 m Clear cell renal cell carcinoma
- 23:36, 18 April 2024 diff hist +730 m Clear cell renal cell carcinoma - null regimens →Placebo current
- 20:40, 18 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive →Regimen {{#subobject:9cef11|Variant=1}}
- 20:39, 18 April 2024 diff hist +255 m Alectinib (Alecensa) →History of changes in FDA indication current
- 17:14, 16 April 2024 diff hist -1 m Drug shortages →Links current
- 19:37, 15 April 2024 diff hist +38 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & TBI, then auto HSCT {{#subobject:9ac748|Regimen=1}}
- 19:31, 15 April 2024 diff hist 0 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:30, 15 April 2024 diff hist +308 m Multiple myeloma - historical →MEL200, then auto HSCT, then MEL220 & Dexamethasone, then auto HSCT {{#subobject:9f3119|Regimen=1}}
- 19:25, 15 April 2024 diff hist +330 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:20, 15 April 2024 diff hist -1 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisolone (TP) {{#subobject:1agdc9|Regimen=1}}
- 18:42, 15 April 2024 diff hist +255 m Follicular lymphoma - historical →131Iodine-Tositumomab monotherapy {{#subobject:f69726|Regimen=1}}
- 17:48, 15 April 2024 diff hist -1 m Breast cancer - historical →CEF/CMF {{#subobject:682333|Regimen=1}}
- 17:04, 15 April 2024 diff hist +16 m CNS lymphoma →Nordic Regimen, younger patients {{#subobject:e571ce|Regimen=1}}
- 17:02, 15 April 2024 diff hist +2 m Rhabdomyosarcoma, pediatric
- 17:35, 14 April 2024 diff hist -39 m Urothelial carcinoma - null regimens →Preceding treatment current
- 17:35, 14 April 2024 diff hist -13 m Urothelial carcinoma →Preceding treatment
- 17:34, 14 April 2024 diff hist +12 m Urothelial carcinoma - null regimens →Preceding treatment
- 17:33, 14 April 2024 diff hist +9 m Testicular cancer →Regimen variant #5, 45/500/100 (modified BEP) {{#subobject:fd61db|Variant=1}}